Avidity (RNA): Price to Sales

Symbol and logo of brand Avidity Biosciences Inc (RNA)

The current P/S multiple reflects market expectations, where 585.30 represents the current metric value for Avidity Biosciences (RNA). This trend is driven by strong biotech patents that ensure high margins. Meanwhile, drug production is outsourced to third-party contractors, creating a dependency on their stability. In the future, successful clinical trials could grant the company monopoly pricing power over rare therapies.

Avidity Biosciences, Inc. (RNA): P/S Multiple from 07/04/2022 to 02/27/2026

Analytical breakdowns for Avidity (RNA)

- price and consensus price forecast:
Market Chart aviditybiosciences.com|RNA - Price Target Chart
- stock exchange capitalization data:
Market Value Avidity|RNA - Total Company Value
- shareholders' equity book value data:
Net Assets per Share Avidity Biosciences|RNA - Book Capitalization|Market Cap to Net Assets Ratio aviditybiosciences.com|RNA - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Avidity Biosciences|RNA - Long-Term Debt to Capital|Current Liabilities to Capital Avidity Corp|RNA - Company Debts|Debt to Book Value Ratio Avidity|RNA - Company Long-Term Debts|Company Current Liabilities Avidity Biosciences|Immediate Liquidity aviditybiosciences.com
- net income and valuation ratios data:
RNA - Company Net Income|Company Profit Forecast Avidity Biosciences|RNA - Price to Earnings Ratio|Future Price to Earnings Multiple Avidity Biosciences Inc|RNA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Avidity|RNA - Operating profit EBITDA|Net earnings per share (EPS TTM) Avidity Biosciences|RNA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months aviditybiosciences.com|RNA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Avidity Biosciences
- issuer revenue and sales details:
RNA - Revenue and Sales Volume|Projected Sales Volume aviditybiosciences.com|RNA - P/S Multiple|Forward P/S Multiple Avidity
Fundamental company analysis:aviditybiosciences.com (RNA)
Core merchandise of Avidity Biosciences, Inc.

For Avidity Biosciences (RNA), which operates in an undersaturated RNA therapeutics market, the P/S ratio reflects market expectations for future sales of innovative drugs. This metric is calculated as the ratio of market capitalization to annual revenue, measuring the value of each dollar of income in the eyes of investors. By analyzing the P/S chart, one can assess the extent to which the premium for breakthrough technologies is justified within the context of an expanding patient base.

Competing companies

Price-to-Revenue Coefficient Tempus AI|Price-to-Revenue Ratio Qiagen QGEN|Ionis Pharmaceuticals, Inc. (IONS) - Price to Sales|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient CRISPR CRSP|WGS: P/S Multiple|Market Cap to Revenue ultragenyx.com|BEAM (Beam Therapeutics) - P/S Multiple|Sarepta Therapeutics (SRPT) - Price-to-Revenue Coefficient|P/S Multiple TWST|TXG - Price to Sales|Price-to-Revenue Ratio Intellia Therapeutics NTLA|STOK: Market Cap to Revenue Ratio|BioLife Solutions - P/S Multiple|Wave Life Sciences Ltd (WVE) - Market Cap to Revenue|MAZE: P/S Multiple|Price to Sales Sionna Corp (SION)|Price-to-Revenue Ratio Prime Medicine, Inc.|tayshagtx.com (TSHA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio uniQure (QURE)|MGTX (MeiraGTx Holdings) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Regenxbio RGNX|SLDB: Market Cap to Revenue Ratio|Ocugen, Inc. - P/S Multiple|PACB - P/S Multiple|BNTC: P/S Multiple|Market Cap to Revenue Ratio DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals Inc|Market Cap to Revenue Ratio FDMT (4D Molecular Corp)|P/S Multiple LXEO|P/S Multiple korrobio.com (KRRO)|P/S Multiple EDIT (Editas Medicine)|P/S Multiple Silence Therapeutics PLC SLN|PRQR: Market Cap to Revenue|CDXS: Price-to-Revenue Ratio|SGMO: P/S Multiple|NAUT - Price-to-Revenue Coefficient|MGX (Metagenomi) - P/S Multiple|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|Price-to-Revenue Coefficient Boundless Bio Inc|Exicure - Market Cap to Revenue|Market Cap to Sales Volume IMNN (Imunon Inc)|PHIO: Market Cap to Revenue|Price to Sales Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|Bionano Genomics - Market Capitalization-to-Revenue Ratio|APDN (Applied DNA Sciences) - P/S Multiple|Price-to-Revenue Ratio BLUE|P/S Multiple IPA|Price-to-Revenue Coefficient Omega Therapeutics Inc|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Regulus (RGLS) - Price to Sales|SYRS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient telesisbio.com TBIO|TCON: P/S Multiple|Market Cap to Revenue Unity Biotechnology Inc.